Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure : The EVEREST clinical status trials
- Author
- GHEORGHIADE, Mihai1 ; KONSTAM, Marvin A2 ; ZIMMER, Christopher10 ; ORLANDI, Cesare10 ; BURNETT, John C3 ; GRINFELD, Liliana4 ; MAGGIONI, Aldo P5 ; SWEDBERG, Karl6 ; UDELSON, James E2 ; ZANNAD, Faiez7 ; COOK, Thomas8 ; OUYANG, John9
[1] Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill, United States
[2] Division of Cardiology, Tufts-New England Medical Center, Boston, Mass, United States
[3] Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minn, United States
[4] Departmento de Diagnostico y Tratamiento, Servicio de Hemodinamia, Hospital Italiano, Buenos Aires, Argentina
[5] Associazione Nazionale Medici Cardiologi Ospedalieri Research Center, Florence, Italy
[6] Sahlgrenska University Hospital/Ostra, Gothenburg, Sweden
[7] Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'lnvestigations Cliniques, Nancy, France
[8] Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, United States
[9] Departments of Biometrics, Otsuka Maryland Research Institute, Rockville, United States
[10] Clinical Development, Otsuka Maryland Research Institute, Rockville, United States
Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators - Source
JAMA, the journal of the American Medical Association. 2007, Vol 297, Num 12, pp 1332-1343, 12 p ; ref : 34 ref
- ISSN
- 0098-7484
- Scientific domain
- General medicine general surgery
- Publisher
- American Medical Association, Chicago, IL
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Antagoniste Court terme Essai clinique Homme Hospitalisation Insuffisance cardiaque Malade Médecine Médicament Tolvaptan Vasopressine Voie orale Appareil circulatoire pathologie Cardiopathie Hormone neurohypophysaire Neuropeptide Récepteur peptidergique Récepteur vasopressine V2
- Keyword (en)
- Antagonist Short term Clinical trial Human Hospitalization Heart failure Patient Medicine Drug Tolvaptan Vasopressin Oral administration Cardiovascular disease Heart disease Neurohypophyseal hormone Neuropeptide Peptidergic receptor V2 vasopressin receptor
- Keyword (es)
- Antagonista Corto plazo Ensayo clínico Hombre Hospitalización Insuficiencia cardíaca Enfermo Medicina Medicamento Tolvaptán Vasopresina Vía oral Aparato circulatorio patología Cardiopatía Hormona neurohipofisaria Neuropéptido Receptor peptidérgico Receptor vasopresina V2
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B12 Cardiology. Vascular system / 002B12A Heart / 002B12A01 Heart failure, cardiogenic pulmonary edema, cardiac enlargement
- Discipline
- Cardiology. Circulatory system Generalities in medical sciences
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 18652659
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1001/jama.297.12.1332 
https://dx.doi.org/10.1001/jama.297.12.1332
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1001\/jama.297.12.1332\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:153:\"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure : The EVEREST clinical status trials\";s:9:\"\u0000*\u0000jtitle\";s:53:\"JAMA, the journal of the American Medical Association\";s:9:\"\u0000*\u0000stitle\";s:22:\"JAMA j. Am. Med. Assoc\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"297\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1332\";s:8:\"\u0000*\u0000epage\";s:4:\"1343\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0098-7484\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"GHEORGHIADE\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Mihai\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:17:\"KONSTAM, Marvin A\";i:1;s:19:\"ZIMMER, Christopher\";i:2;s:15:\"ORLANDI, Cesare\";i:3;s:15:\"BURNETT, John C\";i:4;s:17:\"GRINFELD, Liliana\";i:5;s:16:\"MAGGIONI, Aldo P\";i:6;s:14:\"SWEDBERG, Karl\";i:7;s:16:\"UDELSON, James E\";i:8;s:13:\"ZANNAD, Faiez\";i:9;s:12:\"COOK, Thomas\";i:10;s:12:\"OUYANG, John\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:153:\"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure : The EVEREST clinical status trials\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:28:\"American Medical Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1001\/jama.297.12.1332\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:153:\"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure : The EVEREST clinical status trials\";s:9:\"\u0000*\u0000jtitle\";s:53:\"JAMA, the journal of the American Medical Association\";s:9:\"\u0000*\u0000stitle\";s:22:\"JAMA j. Am. Med. Assoc\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"297\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1332\";s:8:\"\u0000*\u0000epage\";s:4:\"1343\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0098-7484\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"GHEORGHIADE\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Mihai\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:17:\"KONSTAM, Marvin A\";i:1;s:19:\"ZIMMER, Christopher\";i:2;s:15:\"ORLANDI, Cesare\";i:3;s:15:\"BURNETT, John C\";i:4;s:17:\"GRINFELD, Liliana\";i:5;s:16:\"MAGGIONI, Aldo P\";i:6;s:14:\"SWEDBERG, Karl\";i:7;s:16:\"UDELSON, James E\";i:8;s:13:\"ZANNAD, Faiez\";i:9;s:12:\"COOK, Thomas\";i:10;s:12:\"OUYANG, John\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:153:\"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure : The EVEREST clinical status trials\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:28:\"American Medical Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.1001\/jama.297.12.1332\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1001\/jama.297.12.1332\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:153:\"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure : The EVEREST clinical status trials\";s:9:\"\u0000*\u0000jtitle\";s:53:\"JAMA, the journal of the American Medical Association\";s:9:\"\u0000*\u0000stitle\";s:22:\"JAMA j. Am. Med. Assoc\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"297\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1332\";s:8:\"\u0000*\u0000epage\";s:4:\"1343\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0098-7484\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"GHEORGHIADE\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Mihai\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:17:\"KONSTAM, Marvin A\";i:1;s:19:\"ZIMMER, Christopher\";i:2;s:15:\"ORLANDI, Cesare\";i:3;s:15:\"BURNETT, John C\";i:4;s:17:\"GRINFELD, Liliana\";i:5;s:16:\"MAGGIONI, Aldo P\";i:6;s:14:\"SWEDBERG, Karl\";i:7;s:16:\"UDELSON, James E\";i:8;s:13:\"ZANNAD, Faiez\";i:9;s:12:\"COOK, Thomas\";i:10;s:12:\"OUYANG, John\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:153:\"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure : The EVEREST clinical status trials\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:28:\"American Medical Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1001\/jama.297.12.1332\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:153:\"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure : The EVEREST clinical status trials\";s:9:\"\u0000*\u0000jtitle\";s:53:\"JAMA, the journal of the American Medical Association\";s:9:\"\u0000*\u0000stitle\";s:22:\"JAMA j. Am. Med. Assoc\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"297\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1332\";s:8:\"\u0000*\u0000epage\";s:4:\"1343\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0098-7484\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"GHEORGHIADE\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Mihai\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:17:\"KONSTAM, Marvin A\";i:1;s:19:\"ZIMMER, Christopher\";i:2;s:15:\"ORLANDI, Cesare\";i:3;s:15:\"BURNETT, John C\";i:4;s:17:\"GRINFELD, Liliana\";i:5;s:16:\"MAGGIONI, Aldo P\";i:6;s:14:\"SWEDBERG, Karl\";i:7;s:16:\"UDELSON, James E\";i:8;s:13:\"ZANNAD, Faiez\";i:9;s:12:\"COOK, Thomas\";i:10;s:12:\"OUYANG, John\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:153:\"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure : The EVEREST clinical status trials\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:28:\"American Medical Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1001\/jama.297.12.1332\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:153:\"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure : The EVEREST clinical status trials\";s:9:\"\u0000*\u0000jtitle\";s:53:\"JAMA, the journal of the American Medical Association\";s:9:\"\u0000*\u0000stitle\";s:22:\"JAMA j. Am. Med. Assoc\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"297\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"1332\";s:8:\"\u0000*\u0000epage\";s:4:\"1343\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0098-7484\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"GHEORGHIADE\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Mihai\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:17:\"KONSTAM, Marvin A\";i:1;s:19:\"ZIMMER, Christopher\";i:2;s:15:\"ORLANDI, Cesare\";i:3;s:15:\"BURNETT, John C\";i:4;s:17:\"GRINFELD, Liliana\";i:5;s:16:\"MAGGIONI, Aldo P\";i:6;s:14:\"SWEDBERG, Karl\";i:7;s:16:\"UDELSON, James E\";i:8;s:13:\"ZANNAD, Faiez\";i:9;s:12:\"COOK, Thomas\";i:10;s:12:\"OUYANG, John\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:153:\"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure : The EVEREST clinical status trials\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:28:\"American Medical Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
